Wiskott-Aldrich syndrome gene mutations modulate cancer susceptibility in the p53±murine model
Open Access
- 23 July 2018
- journal article
- research article
- Published by Taylor & Francis in OncoImmunology
- Vol. 7 (9) , e1468954
Abstract
The Wiskott-Aldrich syndrome protein (WASp) is a key regulator of the actin cytoskeleton in hematopoietic cells and mutated in two severe immunodeficiency diseases with high incidence of cancer. Wiskott-Aldrich syndrome (WAS) is caused by loss-of-function mutations in WASp and most frequently associated with lymphoreticular tumors of poor prognosis. X-linked neuropenia (XLN) is caused by gain-of-function mutations in WASp and associated with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). To understand the role of WASp in tumorigenesis, we bred WASp+, WASp−, and WASp-XLN mice onto tumor susceptible p53+/- background and sub-lethally irradiated them to enhance tumor development. We followed the cohorts for 24 weeks and tumors were characterized by histology and flow cytometry to define the tumor incidence, onset, and cell origin. We found that p53+/-WASp+ mice developed malignancies, including solid tumors and T cell lymphomas with 71.4% of survival 24 weeks after irradiation. p53+/-WASp− mice showed lower survival rate and developed various early onset malignancies. Surprisingly, the p53+/-WASp-XLN mice developed malignancy mostly with late onset, which caused delayed mortality in this colony. This study provides evidence for that loss-of-function and gain-of-function mutations in WASp influence tumor incidence and onset.Keywords
Funding Information
- Cancer Society
- Olle Engqvist Byggmästare foundation
- Fundação para a Ciência e a Tecnologia to M.M.S.O., and Swedish Research Council, Cancer Society, Childhood Cancer Society
- Åke Olsson foundation, Bergvall Foundation, King Gustaf V’s 80-year Foundation, and Karolinska Institutet to L.S.W. L.S.W. is a Ragnar Söderberg fellow in Medicine
This publication has 35 references indexed in Scilit:
- Somatic mutations activating Wiskott-Aldrich syndrome protein concomitant with RAS pathway mutations in juvenile myelomonocytic leukemia patientsHuman Mutation, 2018
- IL-2 in the tumor microenvironment is necessary for Wiskott-Aldrich syndrome protein deficient NK cells to respond to tumors in vivoScientific Reports, 2016
- Current and emerging treatment options for Wiskott–Aldrich syndromeExpert Review of Clinical Immunology, 2015
- Wiskott-Aldrich Syndrome Protein Regulates Leukocyte-Dependent Breast Cancer MetastasisCell Reports, 2013
- Excess F-actin mechanically impedes mitosis leading to cytokinesis failure in X-linked neutropenia by exceeding Aurora B kinase error correction capacityBlood, 2012
- p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewalGenes & Development, 2010
- A large kindred with X‐linked neutropenia with an I294T mutation of the Wiskott‐Aldrich syndrome geneBritish Journal of Haematology, 2008
- Lymphoid neogenesis and immune infiltration in aged liverHepatology, 2008
- Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: Assessment of an oral agent that stimulates erythropoietin productionProceedings of the National Academy of Sciences, 2005
- Primary immunodeficiencies: genetic risk factors for lymphoma.1992